Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab or talquetamab combinations versus DRd in newly diagnosed multiple myeloma
ISRCTN72661732Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of teclistamab, talquetamab, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and 12-month MRD-negative complete response. Started Oct 2022; status: recruiting.
02
Drugs
teclistamabtalquetamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN72661732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72661732.